RAF1 and melanoma: Type II RAF inhibitors are considered to be pan‐RAF inhibitors, which targeted the unique “DGF‐out” and “αC‐helix‐in” conformations of the kinase, and at least five inhibitors (naporafenib, tovorafenib, belvarafenib, exarafenib, and TAK‐632) showed activity in BRAFmut or RASmut melanoma [179, 180, 181].